JMP Securities Reinstates Minerva Neurosciences (NERV) at Market Outperform

June 5, 2020 2:30 PM EDT
Get Alerts NERV Hot Sheet
Price: $2.46 -3.15%

Rating Summary:
    6 Buy, 2 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 10 | Down: 11 | New: 50
Trade Now! 
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

JMP Securities analyst Jason N. Butler reinstates coverage on Minerva Neurosciences (NASDAQ: NERV) with a Market Outperform rating and a price target of $9.00 (from $18.00).

Analyst comments: "We look to an update following FDA feedback on the next steps with a best case scenario being submission of an NDA based on the currently available data and base case scenario involving conduct of an additional trial pre-approval. Our valuation is driven by the base case scenario and assumes approval and launch of roluperidone by YE 2023 (vs. 2021 prior) and a 60% probability of approval (vs. 70% prior)."

For an analyst ratings summary and ratings history on Minerva Neurosciences click here. For more ratings news on Minerva Neurosciences click here.

Shares of Minerva Neurosciences closed at $4.26 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, New Coverage

Related Entities

JMP Securities, FDA